- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07623824
A Phase III Clinical Trial to Evaluate the Efficacy and Safety of Octreotide Long-acting Injection in Patients With Acromegaly
May 29, 2026 updated by: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
A Randomized, Parallel, Open-label, Multicenter, Positive-controlled, Superiority Phase III Trial to Evaluate the Efficacy and Safety of Octreotide Long-acting Injection in Patients With Acromegaly
he purpose of this study is to evaluate the efficacy and safety of SYHX2008 injection in in patients with acromegaly.
Study Overview
Status
Not yet recruiting
Intervention / Treatment
Detailed Description
This study is a randomized, parallel, open-label, multicenter, positive-controlled, superiority-designed Phase III clinical study evaluating the efficacy and safety of octreotide long-acting injection in patients with acromegaly.
The purpose of this study is to evaluate the efficacy and safety of SYHX2008 injection in treating acromegaly.
Patients will be randomized to SYHX2008 cohort or Octreotide Microspheres(Sandostatin LAR®) cohort.
A total of 154 participants are expected to be enrolled.
The study will consist of a maximum 4-week screening/Baseline period, followed by 28-week treatment period.
Study Type
Interventional
Enrollment (Estimated)
154
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Clinical Trials Information Group officer
- Phone Number: +86311-69085587
- Email: ctr-contact@cspc.cn
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Male or female participants aged 18 to 80 years (including boundary values)
- Diagnosed with acromegaly, currently in the active stage of the disease (for patients who have not undergone pituitary tumor surgery before, MRI shows a pituitary mass, fasting GH ≥ 2.5 ng/mL and IGF-1 index ≥ 1.3; for patients who have undergone pituitary tumor surgery, fasting GH ≥ 2.5 ng/mL and IGF-1 index ≥ 1.3);
Exclusion Criteria:
- Have received pituitary radiotherapy within the 5 years prior to screening
- Have undergone major surgery (including pituitary surgery) within 6 months prior to screening or are expected to require surgery (including pituitary surgery) or radiotherapy during the study period
- Within three months before the screening, participants received drugs such as long-acting lanretide, long-acting octreotide, pervesomone, and cabergoline, or traditional Chinese medicines for treating acromegaly. Receive bromocriptine within one month before screening; Received short-acting octreotide or lanretide short-acting preparations for treatment within 7 days before screening; Or have received any other investigational drug within 30 days before screening or within 5 half-lives (whichever is longer)
- Previous failure to respond to octreotide or lantreotide monotherapy (defined as: after at least 3 months of treatment with octreotide microspheres ≥30 mg or lantreotide ≥120 mg, or after at least 3 months of treatment with parietide microspheres ≥40 mg, random GH ≥2.5 ng/mL and/or IGF-1 index ≥1.3) or history of intolerance.
- Participants with obvious visual field defects caused by optic chiasm compression and requiring surgical intervention
- HbA1c>8.5%
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: SYHX2008
|
The patients will accept SYHX2008 injection by subcutaneous administration.A treatment period of 28 weeks.
|
|
Experimental: Sandostatin LAR®
|
The patients will accept Sandostatin LAR@ by intra-muscular administration.A treatment period of 28 weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The proportion of patients with an IGF-1 index ≤ 1.0
Time Frame: Week 28
|
insulin-like growth factor-1 within the normal range after adjustment for age and gender, where IGF-1 index = IGF-1 value/ULN, and ULN is the upper limit of the normal reference range
|
Week 28
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The proportion of patients with fasting GH less than 2.5 ng/mL and IGF-1 index less than or equal to 1.0
Time Frame: weeks 4、8、12、16、20、24、28
|
weeks 4、8、12、16、20、24、28
|
|
|
The proportion of patients with GH less than 1.0 ng/mL and IGF-1 index less than or equal to 1.0
Time Frame: weeks 4、8、12、16、20、24、28
|
weeks 4、8、12、16、20、24、28
|
|
|
The proportion of patients with fasting GH < 1.0 ng/mL
Time Frame: Weeks 4、8、12、16、20、24、28
|
Weeks 4、8、12、16、20、24、28
|
|
|
The proportion of patients with fasting GH<2.5 ng/mL
Time Frame: Weeks 4、8、12、16、20、24、28
|
Weeks 4、8、12、16、20、24、28
|
|
|
The proportion of patients with an IGF-1 index ≤ 1.0
Time Frame: Weeks 4、8、12、16、20、24
|
insulin-like growth factor-1 within the normal range after adjustment for age and gender, where IGF-1 index = IGF-1 value/ULN, and ULN is the upper limit of the normal reference range
|
Weeks 4、8、12、16、20、24
|
|
The rate of change in the volume of the pituitary tumor from the baseline
Time Frame: Weeks 28
|
Weeks 28
|
|
|
The change in the total PASQ score from the baseline
Time Frame: Weeks 12、28
|
Evaluation of effect on was assessed using Patient Assessed Acromegaly Symptom Question ( PASQ ), an acromegaly-specific quality of life instrument.
|
Weeks 12、28
|
|
The change in the total AcroQoL score from the baseline
Time Frame: Weeks 12、28
|
Evaluation of effect was assessed using Acromegaly Quality of Life Questionnaire(AcroQoL), an acromegaly-specific quality of life instrument.
|
Weeks 12、28
|
|
The proportion of patients with fasting GH decreased by ≥50% compared to the baseline
Time Frame: Weeks 4、8、12、16、20、24、28
|
Weeks 4、8、12、16、20、24、28
|
|
|
The proportion of patients whose IGF-1 index decreased by ≥50% compared with the baseline
Time Frame: Weeks 4、8、12、16、20、24、28
|
Weeks 4、8、12、16、20、24、28
|
|
|
Percentage changes in fasting GH from baseline
Time Frame: Weeks 4、8、12、16、20、24、28
|
Weeks 4、8、12、16、20、24、28
|
|
|
Percentage changes in IGF-1 from baseline
Time Frame: Weeks 4、8、12、16、20、24、28
|
Weeks 4、8、12、16、20、24、28
|
|
|
Incidence of adverse events (AE)
Time Frame: From the signing of informed consent up to 28 Weeks after the first dose
|
Proportion of subjects with adverse events (AEs) within Weeks 28
|
From the signing of informed consent up to 28 Weeks after the first dose
|
|
The concentration of octreotide
Time Frame: From the signing of informed consent up to 28 Weeks afterthe first dose
|
The concentration of octreotide in the plasma of patients with acromegaly after administration of SYHX2008 injection and Sandostatin LAR®
|
From the signing of informed consent up to 28 Weeks afterthe first dose
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
May 31, 2026
Primary Completion (Estimated)
July 31, 2029
Study Completion (Estimated)
December 30, 2029
Study Registration Dates
First Submitted
May 29, 2026
First Submitted That Met QC Criteria
May 29, 2026
First Posted (Actual)
June 3, 2026
Study Record Updates
Last Update Posted (Actual)
June 3, 2026
Last Update Submitted That Met QC Criteria
May 29, 2026
Last Verified
May 1, 2026
More Information
Terms related to this study
Other Study ID Numbers
- SYHX2008-006
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.